SMAD4 and TGFβ are architects of inverse genetic programs during fate-determination of antiviral CTLs

  1. Karthik Chandiran
  2. Jenny E Suarez-Ramirez
  3. Yinghong Hu
  4. Evan R Jellison
  5. Zenep Ugur
  6. Jun-Siong Low
  7. Bryan McDonald
  8. Susan M M Kaech
  9. Linda S Cauley  Is a corresponding author
  1. University of Connecticut Health Center, United States
  2. Emory University, United States
  3. Yale University, Switzerland
  4. Salk Institute for Biological Studies, United States

Abstract

Transforming growth factor β (TGFβ) is an important differentiation factor for cytotoxic T lymphocytes (CTLs) and alters the expression levels of several of homing-receptors during infection. SMAD4 is part of the canonical signaling network used by members of the transforming growth factor family. For this study, genetically-modified mice were used to determine how SMAD4 and TGFβ receptor II (TGFβRII) participate in transcriptional-programing of pathogen-specific CTLs. We show that these molecules are essential components of opposing signaling mechanisms, and cooperatively regulate a collection of genes that determine whether specialized populations of pathogen-specific CTLs circulate around the body, or settle in peripheral tissues. TGFb uses a canonical SMAD-dependent signaling pathway to down-regulate Eomesodermin (EOMES), KLRG1 and CD62L, while CD103 is induced. Conversely, in vivo and in vitro data show that EOMES, KLRG1, CX3CR1 and CD62L are positively-regulated via SMAD4, while CD103 and Hobit are downregulated. Intravascular staining shows that signaling via SMAD4 promotes formation of terminally-differentiated CTLs that localize in the vasculature. Our data shows that inflammatory molecules play a key role in lineage-determination of pathogen-specific CTLs, and use SMAD-dependent signaling to alter the expression levels of multiple homing-receptors and transcription factors with known functions during memory formation.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE151637Figure 3-source data 1 contain the numerical data used to generate the figures

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Karthik Chandiran

    Department of Immunology, University of Connecticut Health Center, Farmington, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2118-7946
  2. Jenny E Suarez-Ramirez

    Department of Immunology, University of Connecticut Health Center, Farmington, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Yinghong Hu

    Department of Microbiology and Immunology, Emory University, Atlanta, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Evan R Jellison

    Department of Immunology, University of Connecticut Health Center, Farmington, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Zenep Ugur

    Department of Immunology, University of Connecticut Health Center, Farmington, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jun-Siong Low

    Department of Immunobiology, Yale University, Bellinzona, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  7. Bryan McDonald

    NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, San Diego, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Susan M M Kaech

    NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, San Diego, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Linda S Cauley

    Department of Immunology, University of Connecticut Health Center, Farmington, United States
    For correspondence
    lcauley@uchc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9488-0341

Funding

National Institute of Allergy and Infectious Diseases (R01 AI123864)

  • Susan M M Kaech
  • Linda S Cauley

American association for Immunologists (AAI Careers in Immunology Fellowship)

  • Linda S Cauley

University of Connecticut Health Center (bridge funding)

  • Linda S Cauley

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Experiments were performed in accordance with protocol AP-200531-0824 approved by the UCONN Health Institutional Animal Care and Use Committee (IACUC). Every effort was made to minimize suffering.

Copyright

© 2022, Chandiran et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,084
    views
  • 263
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Karthik Chandiran
  2. Jenny E Suarez-Ramirez
  3. Yinghong Hu
  4. Evan R Jellison
  5. Zenep Ugur
  6. Jun-Siong Low
  7. Bryan McDonald
  8. Susan M M Kaech
  9. Linda S Cauley
(2022)
SMAD4 and TGFβ are architects of inverse genetic programs during fate-determination of antiviral CTLs
eLife 11:e76457.
https://doi.org/10.7554/eLife.76457

Share this article

https://doi.org/10.7554/eLife.76457

Further reading

    1. Immunology and Inflammation
    Aryeh Solomon, Noa Bossel Ben-Moshe ... Roi Avraham
    Research Article

    Trained immunity (TI) is the process wherein innate immune cells gain functional memory upon exposure to specific ligands or pathogens, leading to augmented inflammatory responses and pathogen clearance upon secondary exposure. While the differentiation of hematopoietic stem cells (HSCs) and reprogramming of bone marrow (BM) progenitors are well-established mechanisms underpinning durable TI protection, remodeling of the cellular architecture within the tissue during TI remains underexplored. Here, we study the effects of peritoneal Bacillus Calmette–Guérin (BCG) administration to find TI-mediated protection in the spleen against a subsequent heterologous infection by the Gram-negative pathogen Salmonella Typhimurium (S.Tm). Utilizing single cell RNA-sequencing and flow cytometry, we discerned STAT1-regulated genes in TI-associated resident and recruited splenic myeloid populations. The temporal dynamics of TI were further elucidated, revealing both early and delayed myeloid subsets with time-dependent, cell-type-specific STAT1 signatures. Using lineage tracing, we find that tissue-resident red pulp macrophages (RPM), initially depleted by BCG exposure, are restored from both tissue-trained, self-renewing macrophages and from bone marrow-derived progenitors, fostering long lasting local defense. Early inhibition of STAT1 activation, using specific JAK-STAT inhibitors, reduces both RPM loss and recruitment of trained monocytes. Our study suggests a temporal window soon after BCG vaccination, in which STAT1-dependent activation of long-lived resident cells in the tissue mediates localized protection.

    1. Immunology and Inflammation
    Yalan Jiang, Pingping He ... Xiaoou Shan
    Research Article

    Type 1 diabetes mellitus (T1DM), known as insulin-dependent diabetes mellitus, is characterized by persistent hyperglycemia resulting from damage to the pancreatic β cells and an absolute deficiency of insulin, leading to multi-organ involvement and a poor prognosis. The progression of T1DM is significantly influenced by oxidative stress and apoptosis. The natural compound eugenol (EUG) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, the potential effects of EUG on T1DM had not been investigated. In this study, we established the streptozotocin (STZ)-induced T1DM mouse model in vivo and STZ-induced pancreatic β cell MIN6 cell model in vitro to investigate the protective effects of EUG on T1DM, and tried to elucidate its potential mechanism. Our findings demonstrated that the intervention of EUG could effectively induce the activation of nuclear factor E2-related factor 2 (NRF2), leading to an up-regulation in the expressions of downstream proteins NQO1 and HMOX1, which are regulated by NRF2. Moreover, this intervention exhibited a significant amelioration in pancreatic β cell damage associated with T1DM, accompanied by an elevation in insulin secretion and a reduction in the expression levels of apoptosis and oxidative stress-related markers. Furthermore, ML385, an NRF2 inhibitor, reversed these effects of EUG. The present study suggested that EUG exerted protective effects on pancreatic β cells in T1DM by attenuating apoptosis and oxidative stress through the activation of the NRF2 signaling pathway. Consequently, EUG holds great promise as a potential therapeutic candidate for T1DM.